{"ModuleTitle": "Company Description", "CompanyName": "Dynavax Technologies Corporation", "Symbol": "DVAX", "Address": "2100 POWELL STREET SUITE 900, EMERYVILLE, California, 94608, United States of America", "Phone": "5108485100", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a fully-integrated biopharmaceutical company focused on developing and\r\ncommercializing novel vaccines. Our first commercial product, HEPLISAV-B\u00ae\r\n(Hepatitis B Vaccine (Recombinant), Adjuvanted) is approved by the United States\r\nFood and Drug Administration (\"FDA\") for prevention of infection caused by all\r\nknown subtypes of hepatitis B virus in adults age 18 years and older. We\r\ncommenced commercial shipments of HEPLISAV-B in January 2018. In Phase 3 trials,\r\nHEPLISAV-B demonstrated faster and higher rates of protection with two doses in\r\none month compared to another currently approved hepatitis B vaccine which\r\nrequires three doses over six months, with a similar safety profile. HEPLISAV-B\r\nis the only two-dose hepatitis B vaccine for adults approved in the U.S. \r\n\r\nVACCINES AND VACCINE ADJUVANTS AND HEPLISAV-B'S NOVEL ADJUVANT 1018\r\n\r\nVaccines are products that stimulate a person's immune system to protect against\r\na specific disease.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f11%2f0001564590-20-010075.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "David F. Novack", "title": "President & Chief Operating Officer"}, {"name": "Michael S. Ostrach", "title": "Chief Financial & Business Officer, Senior VP"}, {"name": "Robert Janssen", "title": "Chief Medical Officer & SVP-Clinical Development"}, {"name": "Ryan Spencer", "title": "Chief Executive Officer & Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}